Dr. Tebib replies

JACQUES TEBIB

J Rheumatol 2009;36;1548
http://www.jrheum.org/content/36/7/1548.2

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Dr. Tebib replies

To the Editor:

We thank Roig-Vilaseca and Hoces-Otero1 for bringing some more weight to our work with concordant clinical conclusions. As suggested by Mäkinen and Hannonen2, an effort has to be made to improve our measurement of disease activity in patients with RA and concomitant FM by using a careful clinical examination, which can diagnose FM and lead the clinician not to use a classical tool of disease activity measurement like the DAS28. In this case, clinical experience may help to assess globally the burden of the 2 diseases but suffer from a lack of objectivity. Another possibility could be to create a correction of the DAS28 when FM is present by using the statistical tool, as we suggest, by analysis of both correlation equation3 when comparing 2 similar populations, as we and Roig-Vilaseca and Hoces-Otero did. However, while this correction could alleviate the problem of overestimation of disease activity, and then allow a stricter adaptation of real inflammatory status to therapeutic strategies, it does not take into account the pain magnification that is increased in FM, leading to the poor tolerance of RA in these patients2.

JACQUES TEBIB, MD. Service de Rhumatologie, CHLS, 14 chemin du Petit Revoyet, Pierre Benite 69495, France. E-mail: tebib@aol.com

REFERENCES


J Rheumatol 2009;36:7; doi:10.3899/jrheum.090172